Ferrà C, de Sanjosé S, Lastra C F, Martí F, Mariño E L, Sureda A, Brunet S, Gallardo D, Berlanga J J, García J, Grañena A
Department of Clinical Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
Bone Marrow Transplant. 1997 Dec;20(12):1075-80. doi: 10.1038/sj.bmt.1701023.
TNF-alpha (Tumor necrosis factor-alpha) is involved in many immunological and inflammatory processes, and might be expected to play an important role in the development of BMT-related complications. Triple therapy (pentoxifylline, ciprofloxacin and prednisone) with known anti-TNF activity was tested in 37 patients undergoing a hematopoietic progenitor transplant (HPT). A control group of 16 patients with similar characteristics was selected among consecutive patients receiving a HTP in a neighboring center who did not receive anti-TNF prophylaxis. Major transplant-related complications were registered (VOD, acute GVHD, infectious episodes, renal failure and mucositis) and survival status. TNF plasma concentrations were determined by ELISA, and pentoxifylline plasma concentrations were determined by HPLC. Among patients treated with pentoxifylline (PTX), ciprofloxacin and steroids, no difference in the mean survival time was observed compared with the control group. The incidence of procedure-related death up to day +35 was 11% in the study group and 6% in the control group. In spite of a tendency to a lower incidence of mucositis there was a higher incidence of infections (positive blood cultures) in the study group (49%) than in the control group (16.7%) (P = 0.16). This difference achieved statistical significance in patients receiving an allogeneic HPT (P = 0.05). It is likely that the use of steroids in the early period after transplant increases infectious episodes and makes control of GVHD difficult. The combined administration of steroids with pentoxifylline and ciprofloxacin has not proved beneficial in preventing mucositis, renal failure, VOD or GVHD, or in improving patient survival.
肿瘤坏死因子-α(TNF-α)参与许多免疫和炎症过程,可能在骨髓移植相关并发症的发生发展中起重要作用。对37例接受造血祖细胞移植(HPT)的患者进行了具有已知抗TNF活性的三联疗法(己酮可可碱、环丙沙星和泼尼松)测试。在邻近中心接受造血干细胞移植且未接受抗TNF预防的连续患者中,选择了16例具有相似特征的患者作为对照组。记录主要的移植相关并发症(肝静脉闭塞病、急性移植物抗宿主病、感染发作、肾衰竭和粘膜炎)及生存状况。通过酶联免疫吸附测定法(ELISA)测定血浆TNF浓度,通过高效液相色谱法(HPLC)测定血浆己酮可可碱浓度。在接受己酮可可碱(PTX)、环丙沙星和类固醇治疗的患者中,与对照组相比,平均生存时间未见差异。研究组至第35天与手术相关的死亡率为11%,对照组为6%。尽管粘膜炎的发生率有降低趋势,但研究组(49%)的感染(血培养阳性)发生率高于对照组(16.7%)(P = 0.16)。在接受异基因造血祖细胞移植的患者中,这种差异具有统计学意义(P = 0.05)。移植后早期使用类固醇可能会增加感染发作次数,并使移植物抗宿主病的控制变得困难。联合使用类固醇与己酮可可碱和环丙沙星在预防粘膜炎、肾衰竭肝静脉闭塞病或移植物抗宿主病或改善患者生存方面未显示有益效果。